Target Name: VPS13D
NCBI ID: G55187
Review Report on VPS13D Target / Biomarker Content of Review Report on VPS13D Target / Biomarker
VPS13D
Other Name(s): VPS13D variant 1 | vacuolar protein sorting 13 homolog D | Vacuolar protein sorting 13 homolog D, transcript variant 2 | Vacuolar protein sorting-associated protein 13D | vacuolar protein sorting-associated protein 13D | VP13D_HUMAN | Intermembrane lipid transfer protein VPS13D (isoform 1) | Intermembrane lipid transfer protein VPS13D | VPS13D variant 2 | bridge-like lipid transfer protein family member 5D | SCAR4 | Vacuolar protein sorting 13 homolog D, transcript variant 1 | vacuolar protein sorting 13D | BLTP5D | Intermembrane lipid transfer protein VPS13D (isoform 2) | KIAA0453

VPS13D: A Protein with Multiple Roles in Body's Physiological Processes

VPS13D (VPS13D variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the voltage-dependent potassium channels (VDCs) family, which are involved in the regulation of ion channels and their activities.

The VPS13D protein has been shown to play a role in a variety of physiological processes, including the regulation of muscle contractions, the contraction and relaxation of blood vessels, and the regulation of ion channels in the brain. It is also involved in the regulation of pain perception and the modulation of neurotransmitter release.

In addition to its role in physiological processes, VPS13D has also been shown to be a potential drug target. Studies have shown that VPS13D is a strong predictor of mortality in patients with heart failure, a condition that is characterized by the failure of the heart to pump enough blood to meet the body's needs. In addition, VPS13D has been shown to be involved in the regulation of the immune response, which is a critical function of the body's defenses against infection and disease.

The VPS13D protein is also of interest as a potential biomarker for a variety of diseases, including heart failure, hypertension, and neurodegenerative disorders. Studies have shown that VPS13D is expressed in the brains of patients with Alzheimer's disease, a condition characterized by the progressive loss of brain cells and the development of cognitive impairments. In addition, VPS13D has been shown to be involved in the regulation of neurotransmitter release in the brain, which is a critical function of the brain's defenses against infection and disease.

In conclusion, VPS13D is a protein that has important roles in various physiological processes in the body, including the regulation of muscle contractions, the contraction and relaxation of blood vessels, and the regulation of ion channels in the brain. It is also involved in the regulation of pain perception and the modulation of neurotransmitter release. In addition, VPS13D has been shown to be a potential drug target and a potential biomarker for a variety of diseases, including heart failure, hypertension, and neurodegenerative disorders. Further research is needed to fully understand the role of VPS13D in these processes and to develop effective treatments for these conditions.

Protein Name: Vacuolar Protein Sorting 13 Homolog D

Functions: Mediates the transfer of lipids between membranes at organelle contact sites (By similarity). Functions in promoting mitochondrial clearance by mitochondrial autophagy (mitophagy), also possibly by positively regulating mitochondrial fission (PubMed:29307555, PubMed:29604224). Mitophagy plays an important role in regulating cell health and mitochondrial size and homeostasis

The "VPS13D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS13D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

VPS16 | VPS18 | VPS25 | VPS26A | VPS26AP1 | VPS26B | VPS26C | VPS28 | VPS29 | VPS33A | VPS33B | VPS35 | VPS35L | VPS36 | VPS37A | VPS37B | VPS37C | VPS37D | VPS39 | VPS41 | VPS45 | VPS4A | VPS4B | VPS50 | VPS51 | VPS51P8 | VPS52 | VPS53 | VPS54 | VPS72 | VPS8 | VPS9D1 | VPS9D1-AS1 | VRK1 | VRK2 | VRK3 | VRTN | VSIG1 | VSIG10 | VSIG10L | VSIG10L2 | VSIG2 | VSIG4 | VSIG8 | VSIR | VSNL1 | VSTM1 | VSTM2A | VSTM2A-OT1 | VSTM2B | VSTM2B-DT | VSTM2L | VSTM4 | VSTM5 | VSX1 | VSX2 | VTA1 | VTCN1 | VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P | WASH complex | WASH2P | WASH3P | WASH4P | WASH5P